Trial Profile
A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Sapanisertib (Primary)
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 29 Dec 2022 Status changed from discontinued to completed.
- 20 Oct 2022 Status changed to discontinued, according to Results published in the Investigational New Drugs
- 20 Oct 2022 Results assessing treatment-related grade 3 adverse events and response published in the Investigational New Drugs